Applied DNA to Present at the Imperial Capital 2020 Security Investor Conference on December 3
Applied DNA Sciences, Inc. (NASDAQ: APDN) ("Applied DNA" or the "Company"), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced that it is scheduled to participate virtually in the Imperial Capital 2020 Security Investor Conference on Thursday, December 3, 2020. Dr. James A. Hayward, chief executive officer, will present at 10:45 a.m. EST that day and host one-on-one meetings throughout the day.
An archived webcast will be available within 24 hours of the live presentation on the "IR Calendar" section of the Applied DNA Investor Relations page at adnas.com.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
The Company's common stock is listed on NASDAQ under ticker symbol ?APDN', and its publicly traded warrants are listed on OTC under ticker symbol ?APPDW'.
Applied DNA is a member of the Russell Microcap® Index.
IANS Research, the leading provider of independent research and advisory services for the information security industry, has announced a new strategic investment from the Apax Digital Fund II (the "Apax Digital Funds").
IANS is a widely recognized...
Monster Energy Releases Nine-Minute Video Showcasing Professional Snowboarders Ståle Sandbech, Torgeir Bergrem, and Rene Rinnekangas Riding Beneath the Northern Lights in the Backcountry of Norway
"We had this vision or this idea to...
The University of Maryland's Robert H. Smith School of Business has launched the Center for Artificial Intelligence in Business to conduct research and outreach in order to realize the potential of AI through intentional design and governance...
Curio Digital Therapeutics Inc. announced that the U.S. Food and Drug Administration (FDA) has granted clearance to MamaLift PlusTM. MamaLift Plus is the first prescription digital therapeutic for the treatment of postpartum depression (PPD), a...
Cantaloupe, Inc. , a leading provider of end-to-end technology solutions for self-service commerce, today announced that management will host a webcast to discuss its financial results for the third quarter of fiscal year 2024 on Thursday, May 9,...
DRI Healthcare Trust (the "Trust") announces the closing of its previously announced preferred securities refinancing, whereby its US$114,760,000 aggregate principal amount of Series A and Series B preferred securities and 6,369,180 warrants were...
